Literature DB >> 18293821

Optimization of the perfusion circuit and its possible impact on the inflammatory response.

Filip De Somer1.   

Abstract

Although there has been a steady improvement in cardiopulmonary bypass (CPB) techniques since its early introduction, it is still associated with some morbidity. Further attenuation of bypass-related systemic inflammatory reaction demands multidisciplinary action because the basic physiopathology is complex and cannot be controlled by one approach alone. This is an overview of the literature. Introduction of "mini" CPB circuits makes it easier to compare perfusion outcomes between different centers. Indeed, these circuits have a comparable fluid dynamic characteristic and surface area. All of them have a hemocompatible coating, and the technique avoids return of the pleuropericardial aspirations into the systemic circulation. As a consequence, results are very comparable to those obtained by beating heart surgery. However, vascular access and the resultant change in flow pattern in the aorta still have a negative correlation with neurocognitive outcome. A better understanding of the delicate balance between fluid dynamics, foreign material, coagulation, and inflammation is still a major requirement, especially because recent research combining pharmacologic, surgical, and anesthesia techniques with perfusion techniques has shown attenuation of the inflammatory response sequelae. For example, a better neurologic outcome is achieved by combining separation of suction, reducing hemodilution, administration of high-dose aprotinin, and volatile anesthetics and alternative cannulation techniques. Further improvement of CPB requires more uniform CPB circuits with known characteristics. The design should be based on evidence-based medicine philosophy. Combined efforts should be made by anesthesiologists, perfusionists, and surgeons to attenuate contact activation, ischemia-reperfusion injury, blood-material interaction, cell damage, and neurocognitive outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18293821      PMCID: PMC4680699     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  35 in total

1.  The independent effects of cardiopulmonary bypass hemodilutional anemia and transfusions on CABG outcomes.

Authors:  Robert H Habib; Anoar Zacharias; Thomas A Schwann; Christopher J Riordan
Journal:  Eur J Cardiothorac Surg       Date:  2005-09       Impact factor: 4.191

2.  Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery.

Authors:  Keyvan Karkouti; George Djaiani; Michael A Borger; William S Beattie; Ludwik Fedorko; Duminda Wijeysundera; Joan Ivanov; Jacek Karski
Journal:  Ann Thorac Surg       Date:  2005-10       Impact factor: 4.330

3.  Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.

Authors:  Peter K Smith; Michel Carrier; John C Chen; Axel Haverich; Jerrold H Levy; Philippe Menasché; Stanton K Shernan; Frans Van de Werf; Peter X Adams; Thomas G Todaro; Edward Verrier
Journal:  Ann Thorac Surg       Date:  2006-09       Impact factor: 4.330

4.  Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery.

Authors:  K Karkouti; W S Beattie; D N Wijeysundera; V Rao; C Chan; K M Dattilo; G Djaiani; J Ivanov; J Karski; T E David
Journal:  J Thorac Cardiovasc Surg       Date:  2005-02       Impact factor: 5.209

5.  Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass.

Authors:  F De Somer; Y Van Belleghem; F Caes; K François; H Van Overbeke; J Arnout; Y Taeymans; G Van Nooten
Journal:  J Thorac Cardiovasc Surg       Date:  2002-05       Impact factor: 5.209

6.  Aprotinin inhibits protease-dependent platelet aggregation and thrombosis.

Authors:  Tanveer A Khan; Cesario Bianchi; Pierre Voisine; Jennifer Sandmeyer; Jun Feng; Frank W Sellke
Journal:  Ann Thorac Surg       Date:  2005-05       Impact factor: 4.330

7.  Removal of glucose from the cardiopulmonary bypass prime: a prospective clinical audit.

Authors:  R F Newland; R A Baker; A L Mazzone; J Ottens; A J Sanderson; J R Moubarak
Journal:  J Extra Corpor Technol       Date:  2004-09

8.  Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass.

Authors:  J H Chung; N Gikakis; A K Rao; T A Drake; R W Colman; L H Edmunds
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

9.  Activation of fibrinolysis in the pericardial cavity after cardiopulmonary bypass.

Authors:  Philipe N Khalil; Mohamed Ismail; Peter Kalmar; Georg von Knobelsdorff; Guy Marx
Journal:  Thromb Haemost       Date:  2004-09       Impact factor: 5.249

10.  Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study.

Authors:  Karine Julier; Rafaela da Silva; Carlos Garcia; Lukas Bestmann; Philippe Frascarolo; Andreas Zollinger; Pierre-Guy Chassot; Edith R Schmid; Marko I Turina; Ludwig K von Segesser; Thomas Pasch; Donat R Spahn; Michael Zaugg
Journal:  Anesthesiology       Date:  2003-06       Impact factor: 7.892

View more
  2 in total

1.  Clinical efficacy of two-phase leukocyte filtration in high-risk patients undergoing coronary revascularization with cardiopulmonary bypass.

Authors:  Serdar Gunaydin; Thomas Modine; Tamer Sari; Yaman Zorlutuna; Terence Gourlay
Journal:  J Extra Corpor Technol       Date:  2009-09

Review 2.  Hemolysis in cardiac surgery patients undergoing cardiopulmonary bypass: a review in search of a treatment algorithm.

Authors:  Leen Vercaemst
Journal:  J Extra Corpor Technol       Date:  2008-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.